tiprankstipranks
Advertisement
Advertisement

DE:GE9 Stock Latest News

Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
The FlyWix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls
14d ago
TW
AGX
Genmab initiated with an Outperform at Wolfe Research
PremiumThe Fly
Genmab initiated with an Outperform at Wolfe Research
15d ago
GMAB
Netflix upgraded, Pinterest downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Netflix upgraded, Pinterest downgraded: Wall Street’s top analyst calls
1M ago
AZZ
FPS
Genmab initiated with an Overweight at Wells Fargo
PremiumThe Fly
Genmab initiated with an Overweight at Wells Fargo
1M ago
GMAB
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
PremiumRatings
Genmab: Overvalued Amid Earnings Pressure, Dilutive Merus Deal, and Rising Patent‑Cliff Risks
2M ago
GMAB
Genmab price target lowered to $40 from $45 at Guggenheim
PremiumThe FlyGenmab price target lowered to $40 from $45 at Guggenheim
2M ago
GMAB
Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target
Premium
Ratings
Genmab: Solid Royalties and Strategic Deals, But 2026 Data Risks Justify Maintaining a Hold at $32 Target
2M ago
GMAB
Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside
Premium
Ratings
Buy Rating Backed by 2026 Oncology Catalysts and Margin Outperformance Driving 40%+ Mid-Term EPS Upside
2M ago
GMAB
Genmab price target raised to $40 from $39 at H.C. Wainwright
PremiumThe Fly
Genmab price target raised to $40 from $39 at H.C. Wainwright
2M ago
GMAB
Genmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
PremiumRatings
Genmab: Near-Term Guidance Miss Offset by Strong Results and Blockbuster Late-Stage Pipeline Upside
2M ago
GMAB
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
PremiumThe Fly
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
2M ago
JNJ
GMAB
Genmab resumed with a Buy at Jefferies
PremiumThe Fly
Genmab resumed with a Buy at Jefferies
2M ago
GMAB
Genmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
PremiumRatingsGenmab: De-Risked Long-Term Profile and 2026 Clinical Catalysts Support Buy Rating and DKK 2,650 Target
2M ago
GMAB
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
Premium
Ratings
Genmab: Early-Stage Transition to Fully Integrated Biotech Warrants Balanced ‘Hold’ Amid 2026 Data Catalysts and Execution Risks
2M ago
GMAB
Genmab resumed with an Equal Weight at Morgan Stanley
Premium
The Fly
Genmab resumed with an Equal Weight at Morgan Stanley
2M ago
GMAB
0MGB Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
0MGB Upcoming Earnings Report: What to Expect?
2M ago
AI Daily: Nvidia invests $2B in CoreWeave
PremiumThe Fly
AI Daily: Nvidia invests $2B in CoreWeave
2M ago
LLY
NVS
Drugmakers use AI to help progress through trials, submissions, Reuters says
PremiumThe Fly
Drugmakers use AI to help progress through trials, submissions, Reuters says
2M ago
GSK
LLY
Genmab reports worldwide net sales of Darzalex in 2025 totaled $14.351B
PremiumThe Fly
Genmab reports worldwide net sales of Darzalex in 2025 totaled $14.351B
3M ago
JNJ
GMAB
Genmab: Diversified Oncology Pipeline Supports Upside and Maintained Buy Rating Despite EPKINLY Phase 3 Setback
PremiumRatingsGenmab: Diversified Oncology Pipeline Supports Upside and Maintained Buy Rating Despite EPKINLY Phase 3 Setback
3M ago
GMAB
Genmab price target lowered to $39 from $41 at H.C. Wainwright
Premium
The Fly
Genmab price target lowered to $39 from $41 at H.C. Wainwright
3M ago
GMAB
Genmab price target raised to $38.50 from $34.70 at BofA
Premium
The Fly
Genmab price target raised to $38.50 from $34.70 at BofA
3M ago
GMAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >